OverviewSuggest Edit

BillionToOne is a precision diagnostics company offering a prenatal cystic fibrosis and spinal muscular atrophy screening option that tests fetal cell-free DNA through a single tube of the mother’s blood. The Company operates a molecular counter platform that can accurately count the DNA molecules to the single-count level. 

HQMenlo Park, CA, US
Employee Ratings4

Latest Updates

Employees (est.) (Jul 2021)83(+19%)
Cybersecurity ratingAMore

Key People/Management at BillionToOne

Oguzhan Atay

Oguzhan Atay

Co-Founder and CEO
David Tsao

David Tsao

Co-Founder and CTO
Nipun Soni

Nipun Soni

John Ten Bosch

John Ten Bosch

Laboratory Director
Shan Riku

Shan Riku

SVP of Product
Brent Kirk

Brent Kirk

Director, Sales Strategy and Operations
Show more

BillionToOne Office Locations

BillionToOne has an office in Menlo Park
Menlo Park, CA, US (HQ)
1455 Adams Dr #1130Menlo
Show all (1)

BillionToOne Financials and Metrics

Summary Metrics

Founding Date


BillionToOne total Funding

$87.5 m

BillionToOne latest funding size

$55 m

Time since last funding

22 days ago

BillionToOne investors

BillionToOne's latest funding round in July 2021 was reported to be $55 m. In total, BillionToOne has raised $87.5 m
Show all financial metrics

BillionToOne Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

BillionToOne Online and Social Media Presence

Embed Graph

BillionToOne News and Updates

BillionToOne Closes $55M Series B Funding, Builds Out a 36,000 Sqft Space to Meet Growing Demand

To meet the significant surge in demand, BillionToOne expands its CLIA laboratory space and its commercial team

BillionToOne Granted FDA Emergency Use Authorization for Groundbreaking RNA Extraction-Free qSanger-COVID-19 Assay

BillionToOne's unique testing protocol removes costly, time-consuming step of RNA extraction and significantly expands testing capacity

BillionToOne Announces Groundbreaking New COVID-19 Test Unlocking One Million Daily Tests

Unique Testing Protocol From Precision Diagnostics Company Unlocks One Million Tests Per Day: The BillionToOne COVID-19 test uses different sets of instruments and chemicals from existing COVID-19 tests, enabling labs to unlock a new set of unused capacity.

BillionToOne, Inc., announced today that it has closed its follow-on Series A+ funding round of $15 million

BillionToOne has raised more than $32.5 million. The funding will be used to support the commercial expansion of UNITY™ to all US states

BillionToOne, Inc. and Eluthia Launch UNITY™ Test, the First Non-Invasive Prenatal Test for Cystic Fibrosis, Spinal Muscular Atrophy and Hemoglobinopathies in Germany, Austria, Switzerland and the Netherlands

BillionToOne and Eluthia have announced today the launch of the first and only non-invasive prenatal test, allowing to screen for the autosomal-recessive conditions cystic fibrosis, spinal muscular atrophy (SMA), sickle cell disease and other hemoglobinopathies. The UNITY™ screen will be made availa…
Show more

BillionToOne Frequently Asked Questions

  • When was BillionToOne founded?

    BillionToOne was founded in 2016.

  • Who are BillionToOne key executives?

    BillionToOne's key executives are Oguzhan Atay, David Tsao and Nipun Soni.

  • How many employees does BillionToOne have?

    BillionToOne has 83 employees.

  • Who are BillionToOne competitors?

    Competitors of BillionToOne include ReCode Therapeutics, RheoDx and VivoSensMedical.

  • Where is BillionToOne headquarters?

    BillionToOne headquarters is located at 1455 Adams Dr #1130Menlo, Menlo Park.

  • Where are BillionToOne offices?

    BillionToOne has an office in Menlo Park.

  • How many offices does BillionToOne have?

    BillionToOne has 1 office.